MEG3 and neoplasm: During the gene therapy of OS, engineered exosomes modified by cyclic RGD peptide (cRGD-Exo-MEG3) demonstrated 2.5-fold tumor targeting ability and twofold antitumor effects in vivo compared with Exo-MEG3 [114].